Takeda Sues Generic Makers Over Diabetes Drug Patents

Law360, New York (October 22, 2003, 12:00 AM EDT) -- Japan's largest pharmaceutical company, Takeda Chemical Industries, and its U.S. subsidiary filed lawsuits against three generic drug makers for patent infringement in the U.S. District Court for the Southern District of New York, the company said in a statement.

The lawsuit was filed under the provisions of the Hatch-Waxman Act in response to Abbreviated New Drug Applications (ANDA) filings with the U.S. Food and Drug Administration by Mylan Pharmaceuticals, Watson Pharmaceuticals and Ranbaxy Laboratories for pioglitazone tablets, generic versions of TPNA's ACTOS (pioglitazone HCl). Takeda has...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.